Mon panier

PE-Labeled Monoclonal Anti-Human 4-1BB Antibody, Mouse IgG1 (0.03% Proclin)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
FABm038-01-200tests (50tests X 4)
$200.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Source

    Monoclonal Anti-Human 4-1BB Antibody, Mouse IgG1 is a chimeric monoclonal antibody recombinantly produced from CHO cells, which combines the variable region of a human monoclonal antibody with mouse IgG1 constant domain, which provides higher batch consistency and long term security of supply.

  • Antibody Type

    Recombinant Monoclonal

  • Isotype

    Mouse IgG1, Kappa

  • Host Species

    Rabbit

  • Conjugate

    PE

    Excitation Wavelength: 488 nm / 561 nm

    Emission Wavelength: 575 nm

  • Application

    Flow Cytometry (Detection the expression of 4-1BB on Human cells).

  • Recommended Dilution

    1:20

  • Isotype Control

    The isotype control is sold separately; please refer to Cat. No. DNP-PM1 for product information.

  • Form

    Liquid

  • Formulation

    Supplied as 0.2 μm-filtered solution in PBS (pH 7.4) containing 0.03% ProClin 300 and 0.2% BSA, with trehalose as protectant.

    Please contact us for customized product forms or formulations.

  • Shipping

    Liquid product is shipped at blue ice.

  • Storage

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. Store at 2-8 °C for 12 months.
  • Notices

    Product Specific Notices: For research use only.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • Bioactivity-FACS

     4-1BB FACS

    Flow cytometric analysis of HEK293/Human 4-1BB / TNFRSF9 Stable Cell Line staining with PE-Labeled Monoclonal Anti-Human 4-1BB Antibody, Mouse IgG1 (Cat. No. FABm038-01) at 1:20 dilution (5 μL of the antibody stock solution corresponds to labeling of 1e6 cells in a final volume of 100 µL), compared with isotype control antibody. PE signal was used to evaluate the binding activity (QC tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

4-1BB, also known as CD137 and TNFRSF9, is an approximately 30 kDa transmembrane glycoprotein in the TNF receptor superfamily. 4-1BB functions in the development and activation of multiple immune cells. Mature human 4-1BB consists of a 163 amino acid (aa) extracellular domain (ECD) with four TNFR cysteine-rich repeats, a 27 aa transmembrane segment, and a 42 aa cytoplasmic domain . Within the ECD, human 4-1BB shares 60% aa sequence identity with mouse and rat 4-1BB. 4-1BB is expressed as a disulfide-linked homodimer on various populations of activated T cell including CD4, CD8, memory CD8, NKT, and regulatory T cells as well as on myeloid and mast cell progenitors, dendritic cells, mast cells, and bacterially infected osteoblasts . It binds with high affinity to the transmembrane 4-1BB Ligand/TNFSF9 which is expressed on antigen presenting cells and myeloid progenitor cells . This interaction costimulates the proliferation, activation, and/or survival of the 4-1BB expressing cell . It can also enhance the activation-induced cell death of repetitively stimulated T cells . Mice lacking 4-1BB show augmented T cell activation, perhaps due to its absence on regulatory T cells . 4-1BB can associate with OX40 on activated T cells, forming a complex that responds to either ligand and inhibits Treg and CD8 T cell proliferation . Reverse signaling through 4-1BB Ligand inhibits the development of dendritic cells, B cells, and osteoclasts but supports mature dendritic cell survival and costimulates the proliferation and activation of mast cells.
4-1BB activation enhances CD8 T cell and NK cell mediated anti-tumor immunity . It also contributes to the development of inflammation in high fat diet-induced metabolic syndrome . Soluble forms of 4-1BB and 4-1BB Ligand circulate at elevated levels in the serum of rheumatoid arthritis and hematologic cancer patients, respectively .

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Tumor necrosis factor receptor superfamily member 9

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    77 Détails

  • Étape de développement la plus élevée:

    Phase 3 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte